{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:24Z","timestamp":1791924204791,"version":"4.3.4"},"reference-count":17,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>At Massachusetts General Hospital, we pioneered simultaneous hematopoietic cell (HCT)\/kidney transplantation from HLA-identical related donors for the treatment of hematological malignancies with end-stage renal failure. We have now extended this to HLA-haploidentical donors in a pilot trial. Six recipients, 5 of whom were conditioned with fludarabine, cyclophosphamide, and total-body irradiation, underwent combined HCT\/kidney transplantation from haploidentical donors; graft-versus-host disease (GVHD) prophylaxis included post-HCT cyclophosphamide, tacrolimus, and mycophenolate mofetil. One patient died as a result of complications of fludarabine neurological toxicity. No neurological toxicity was observed in subsequent patients who received lower fludarabine doses and more intense postfludarabine dialysis. There were no cases of grade 2 to 4 acute GVHD and 1 case of moderate chronic GVHD by 12 months. One patient experienced relapse of multiple myeloma at 30 months after HCT and died 4 years posttransplantation. Overall, 4 of 6 patients remain alive, without disease relapse and with long-term renal rejection\u2013free survival. This trial was registered at www.clinicaltrials.gov as #NCT01758042.<\/jats:p>","DOI":"10.1182\/blood.2019000775","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T02:36:34Z","timestamp":1559356594000},"page":"211-215","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"first","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6466-7347","authenticated-orcid":false,"given":"Nahel","family":"Elias","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Transplant Surgery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot","family":"Heher","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0795-497X","authenticated-orcid":false,"given":"Jeannine S.","family":"McCune","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Pharmaceutics, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Collier","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Li","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Del Rio","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfred","family":"Williams","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tolkoff-Rubin","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Fishman","sequence":"additional","affiliation":[{"name":"Transplant Infectious Disease and Compromised Host Program, Massachusetts General Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"McAfee","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimalangshu R.","family":"Dey","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Benedict","family":"Cosimi","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Transplant Surgery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sachs","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Transplant Surgery and"},{"name":"Center for Translational Immunology, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kawai","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Transplant Surgery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021109231043100_B1","doi-asserted-by":"crossref","first-page":"6471901","DOI":"10.1155\/2016\/6471901","article-title":"Combined bone marrow and kidney transplantation for the induction of specific tolerance","volume":"2016","author":"Chen","year":"2016","journal-title":"Adv Hematol"},{"issue":"6","key":"2020021109231043100_B2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/TP.0b013e31820a3068","article-title":"Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease","volume":"91","author":"Spitzer","year":"2011","journal-title":"Transplantation"},{"issue":"6","key":"2020021109231043100_B3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020021109231043100_B4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2020021109231043100_B5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021109231043100_B6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2014.03.003","article-title":"Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning","volume":"20","author":"Raj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020021109231043100_B7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells","volume":"102","author":"Bornhauser","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2020021109231043100_B8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2004.05328.x","article-title":"Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation","volume":"128","author":"Dey","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2020021109231043100_B9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-mismatched renal transplantation without maintenance immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"2020021109231043100_B10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41409-018-0255-9","article-title":"Solid organ transplantation following allogeneic haematopoietic cell transplantation: experience from a referral organ transplantation center and systematic review of literature","volume":"54","author":"Brockmann","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2020021109231043100_B11","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1097\/00007890-200106150-00031","article-title":"Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up","volume":"71","author":"Sellers","year":"2001","journal-title":"Transplantation"},{"issue":"2","key":"2020021109231043100_B12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00007890-199501000-00018","article-title":"Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys","volume":"59","author":"Kawai","year":"1995","journal-title":"Transplantation"},{"issue":"12","key":"2020021109231043100_B13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/bbmt.2001.v7.pm11787527","article-title":"Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance","volume":"7","author":"Mapara","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020021109231043100_B14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0167-5699(88)91352-7","article-title":"Mixed allogeneic chimerism as an approach to transplantation tolerance","volume":"9","author":"Sykes","year":"1988","journal-title":"Immunol Today"},{"issue":"3","key":"2020021109231043100_B15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/ajt.13091","article-title":"Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation","volume":"15","author":"Scandling","year":"2015","journal-title":"Am J Transplant"},{"issue":"124","key":"2020021109231043100_B16","doi-asserted-by":"crossref","first-page":"124ra28","DOI":"10.1126\/scitranslmed.3003509","article-title":"Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation","volume":"4","author":"Leventhal","year":"2012","journal-title":"Sci Transl Med"},{"key":"2020021109231043100_B17","article-title":"Twenty year follow up of histocompatibility leukocyte antigen-matched kidney and bone marrow co-transplantation for multiple myeloma with end stage renal disease: lessons learned [published online ahead of print 12 February 2019]","author":"Spitzer","journal-title":"Transplantation"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/2\/211\/1553913\/bloodbld2019000775.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/2\/211\/1553913\/bloodbld2019000775.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T18:02:33Z","timestamp":1608141753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/2\/211\/260684\/Haploidentical-hematopoietic-cell-and-kidney"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000775","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]}}}